Lawmakers launch investigation into 23AndMe after bankruptcy
A group of House lawmakers launched a probe on Thursday into 23andMe's handling of customers' sensitive data following the company's filing for bankruptcy last month.
In a letter to 23andMe, House Commerce and Energy Committee Chair Brett Guthrie (R-Ky.), Reps. Gus Bilirakis (R-Fla.) and Gary Palmer (R-Ala.) asked the company to state its data privacy and security protections for former customers if the business chooses to sell the personal information in either a standalone sale or as part of a sale of the company.
23andMe, which filed for bankruptcy in Missouri federal court last month, is a human genetics and biotechnology company that became popular in recent years for its at-home DNA tests.
The testing required customers to submit a saliva sample by mail to then receive personalized genetic reports, which has resulted in the company holding the genetic data of more than 15 million customers.
'The company is in possession of highly sensitive personal information, including biological samples, medical information and personal information for more than 15 million customers,' the lawmakers wrote in the letter to Joe Selsavage, the company's interim chief executive officer.
The lawmakers noted Americans' personal health information is shielded under federal privacy laws that restrict the release of medical information, but direct-to-consumer companies like 23andMe are not covered under these laws.
'Given the lack of HIPPA (Health Insurance Portability and Accountability Act) protections, the patchwork of state laws covering genetic privacy, and the uncertainty surrounding what happens to customer information should a sale of the company or customer data and information transpire, we are concerned that this trove of sensitive information is at risk of being compromised, ' the lawmakers wrote.
When the company filed for Chapter 11 bankruptcy last month, it said customers' personal information may be accessed, sold or transferred as part of a transaction and that all possible buyers must comply with its privacy policy and all applicable laws.
Users are able to delete their information from 23andMe's website, though lawmakers on Thursday claimed some customers are having difficulty accessing their data online.
The lawmakers pointed to reports of some customers having difficulty access their data from their 23andMe accounts due to the website being down or issues with verification codes.
'Regardless of whether the company changes ownership, we want to ensure that customer access and deletion requests are being honored by 23andMe,' the lawmakers said.
The letter asks 23andMe a series of questions, including whether it plans to change its privacy statement at any point before selling customers' personal information and if it will vet prospective buyers.
The Hill reached out to the company for further comment.
Other government leaders have raised concerns in recent weeks about 23andMe's data privacy protocols. Earlier this week, the House Committee on Oversight and Government Reform sent an inquiry to the company, following the Federal Trade Commission's letter late last month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
10 minutes ago
- Forbes
Trump Threatens To Nix Musk's Government Contracts, As Friendship Publicly Implodes
President Donald Trump suggested he could revoke Elon Musk's government contracts Thursday as their alliance imploded in a very public fashion over the course of several hours Thursday in a feud over Trump's signature policy bill. President Donald Trump speaks during a news conference with Elon Musk in the Oval Office of the ... More White House in Washington, DC, on May 30, 2025. (Photo by ALLISON ROBBERT/AFP via Getty Images) 'The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts. I was always surprised that Biden didn't do it!' Trump wrote on Truth Social, amid a barrage of attacks from Musk. Trump's threat came after Musk accused Trump of 'ingratitude' and said he would have lost the election without him, after the billionaire donated more than $250 million to help elect him last year. Trump insinuated in an Oval Office press conference Thursday the Tesla CEO opposes his 'One Big Beautiful Bill Act,' which Musk has been ranting about all week, because he is 'upset' the electric vehicle incentive was removed, adding that he's not sure he'll remain friends with Musk and alleging Musk 'knew the inner workings of the bill.' Musk didn't reject the accusation about the EV tax credits in a tweet responding to Trump, writing it was 'very unfair!!' that oil and gas subsidies were left in the bill, adding in a subsequent tweet 'this bill was never shown to me even once and was passed in the dead of night so fast that almost no one in Congress could even read it!' Trump also suggested Musk is suffering from what he refers to as 'Trump derangement syndrome,' which Trump describes as people turning on the president after they leave his administration. Earlier Thursday, Musk reposted a 2013 tweet from Trump that said he was in disbelief and 'embarrassed' Republicans were extending the debt ceiling, captioning the repost 'wise words,' after Trump said Wednesday the debt limit should be 'entirely scrapped' as a provision of his 'One Big Beautiful Bill Act,' which would raise the debt ceiling ahead of its expected expiration date in August. Musk said repeatedly last year he supports eliminating the EV tax credit—statements that hurt Trump's argument he only opposes the bill because it gets rid of the incentive. 'I think we should get rid of all credits,' Musk said in December when asked by a reporter on Capitol Hill if he supports getting rid of the electric vehicle tax credit, Politico reported. The House-passed version of the bill would phase out the $7,500 tax credit for some EV buyers by 2026. $2.4 trillion. That's how much the bill would add to the federal debt over the next decade, according to an estimate by the nonpartisan Congressional Budget office released Wednesday that estimates it would cost $4.2 trillion, mostly from tax cuts, and save $1.8 trillion. 'I'm very disappointed in Elon. I've helped Elon a lot,' Trump said while sitting next to German Chancellor Friedrich Merz in the Oval Office Thursday. Musk—who left his White House role Friday—has fired off dozens of tweets this week attacking Trump's policy bill over the amount it's expected to add to the federal debt. 'I'm sorry, but I just can't stand it anymore,' Musk wrote Tuesday on X in his initial post bashing the legislation, calling it a 'massive, outrageous, pork-filled . . . disgusting abomination.' Musk attacked Trump directly over the bill for the first time since he began his days-long rant moments before Trump sat down with Merz by reposting the president's 2013 tweet about the debt ceiling. In other tweets this week targeting the 'One Big Beautiful Bill,' Musk threatened Republicans who voted for it, warning that 'in November next year, we fire all politicians who betrayed the American people' and calling for lawmakers to 'KILL The BILL.' Until Trump's comments Thursday, House Speaker Mike Johnson, R-La.—who shepherded the bill through the House—was the top Republican defending the legislation against Musk's criticism. Johnson said Wednesday Trump is 'not delighted that Elon did a 180.' The bill, passed by the House in a party-line vote last month after last-minute revisions to appease Republican holdouts, is currently being negotiated by the Senate. Republican leaders have set a July 4 deadline to put the bill on Trump's desk for signage, but GOP resistance in the upper chamber—and some expressions of regret from a few House Republicans who said they were unaware of certain provisions—threaten to delay its passage. The legislation would fulfill Trump's key campaign promises, including an extension of his 2017 tax cuts, no taxes on tips and overtime and additional border security, paid for, in part, by cuts to Medicaid. Tensions between Musk and Trump were palpable during the joint press conference they held Friday to mark Musk's last day leading the Department of Government Efficiency. While the two praised each other, their once-lighthearted rapport appeared stiff and uneasy. Musk in particular appeared to be in an odd mood, prompting social media users to claim he was 'tweaking out,' suggesting he may have been under the influence of drugs, as the press conference was held hours after a New York Times report alleging Musk engaged in heavy drug use while he campaigned for Trump last year. Musk also sported a black eye during the press conference, which the Tesla CEO claimed he got from his five-year-old son. 'KILL The BILL': Musk Deepens Rant Against Trump's Signature Policy Legislation (Forbes) Musk Calls For Ending Electric Vehicle Tax Credit—Which Could Help Tesla (Forbes) Musk Cuts Off Reporter Asking About Drug Use Allegations—Including Ketamine, Ecstasy And Adderall (Forbes)
Associated Press
15 minutes ago
- Associated Press
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate.' The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation.' An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
Bloomberg
34 minutes ago
- Bloomberg
Bankruptcy Was Good for 23andMe
Sometimes a public company has a controlling shareholder who wants to take it private by buying out all of the other shareholders, and that's always messy. 1 The controlling shareholder will to some extent be negotiating with herself: She will want to buy the company for a low price, but the company's shareholders will want to get a high price, but she's the controlling shareholder and can vote for the low price. There are standard solutions to the problem, but they are only partial solutions: In the past few months, I have written a few times about 23andMe Holding Co. as an illustration of these problems. 23andMe is a publicly traded genetic testing company that was once worth about $6 billion, but it has now fallen on hard times. Its founder, Anne Wojcicki, owns about 49% of the voting power of the stock, making her effectively a controlling shareholder. She offered to buy all the stock she didn't own, to take the company private and fix its problems 'outside of the short term pressures of the public markets.' But the board of directors, whose job was to find an 'actionable proposal that is in the best interests of the non-affiliated shareholders,' didn't think her offer was good enough.
